12:00 AM
 | 
Oct 06, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Focalin XR dexmethylphenidate regulatory update

FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) issued a warning letter to Novartis in which the agency said promotional materials for Focalin XR dexmethylphenidate overstate the...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >